ArticleFrontiers in molecular biosciences2026
Preclinical evaluation of waste-derived pomegranate extract (PWE) as a potential preventing and therapeutic agent for benign prostatic hyperplasia.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Benign prostatic hyperplasia (BPH) is a highly prevalent age-related condition, affecting nearly half of men over 60 and up to 80% over 80 years old. Chronic inflammation and oxidative stress are recognized contributors to BPH progression and may facilitate the development of prostate cancer. Growing interest in sustainable, natural chemopreventive agents has highlighted agro-industrial by-products as valuable sources of bioactive compounds. Methods: In this study, we evaluated the protective and therapeutic effects of pomegranate waste extract (PWE), a phytochemical-rich by-product of Mediterranean agri-food processing, in a testosterone-induced rat model of BPH. Results and Discussion: Immunohistochemistry and Western blot analyses revealed that testosterone administration reduced the expression of PECAM-1 and increased the levels of NRF2, HO-1, and IL1R1, consistently with endothelial dysfunction, oxidative stress, and inflammation. Co-treatment with PWE restored these markers toward control levels, indicating attenuation of testosterone-driven molecular alterations. Proteomic profiling further demonstrated that testosterone dysregulated proteins involved in mitochondrial function, redox balance, and DNA repair; on the contrary, PWE normalized their levels and enhanced antioxidant enzymes. In periprostatic adipose tissue, PWE counteracted testosterone-induced upregulation of HO-1, NRF2, and GPX4. Overall, PWE mitigates oxidative, inflammatory, and metabolic dysfunctions associated with experimental BPH, supporting its potential as a sustainable natural chemopreventive strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.